Interventions for treating leg ulcers in people with sickle cell disease

Cochrane Database of Systematic Reviews

Volumn 2014, Issue 12, 2014, Pages

  Martí Carvajal, Arturo J ^a   Knight Madden, Jennifer M ^b   Martinez Zapata, Maria José ^c  

^a Iberoamerican Cochrane Network   (Venezuela)

^b UNIVERSITY OF THE WEST INDIES   (Jamaica)

^c BIOMEDICAL RESEARCH INSTITUTE SANT PAU IIB SANT PAU   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE BUTYRATE; BUTYRIC ACID; CARNITINE; ISOXSUPRINE; SOLCOSERYL; UNCLASSIFIED DRUG; ACTIHAEMYL; ANTIINFECTIVE AGENT; ARGININE; ARGINYL-GLYCYL-ASPARTIC ACID; BUTYRIC ACID DERIVATIVE; OLIGOPEPTIDE;

ALTERNATIVE MEDICINE; CLINICAL EFFECTIVENESS; COMPARATIVE EFFECTIVENESS; DISEASE COURSE; DRUG SAFETY; HUMAN; LEG ULCER; PATIENT CARE; PATIENT SAFETY; PRIORITY JOURNAL; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; SICKLE CELL ANEMIA; SYSTEMATIC REVIEW; TREATMENT RESPONSE; ULCER SIZE; ANALOGS AND DERIVATIVES; BANDAGE; COMPLICATION;

ACTIHAEMYL; ANEMIA, SICKLE CELL; ANTI-BACTERIAL AGENTS; ARGININE; BANDAGES; BUTYRATES; CARNITINE; HUMANS; ISOXSUPRINE; LEG ULCER; OLIGOPEPTIDES; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84925224892     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD008394.pub3     Document Type: Review

References (133)

1. Baum KF, MacFarlane DE, Maude GH, Serjeant GR. Topical antibiotics in chronic sickle cell leg ulcers. Transactions of the Royal Society of Tropical Medicine and Hygiene 1987;81(5):847-9. [PUBMED: 2835836]
2. Macfarlane DE, Baum KF, Maude GH, Serjeant GR. Topical antibiotics in chronic sickle-cell leg ulcers. West Indian Medical Journal 1986;35 Suppl:46-7.
3. La Grenade L, Thomas PW, Serjeant GR. A randomized controlled trial of solcoseryl and duoderm in chronic sickle-cell ulcers. West Indian Medical Journal 1993; Vol. 42, issue 3:121-3. [PUBMED: 8273321]
4. Koshy M, Askin M, McMahon L, Adams-Graves P, Halloway L, Faller DV, et al. Arginine butyrate in sickle cell leg ulcers: interim findings of a phase II trial [abstract]. The National Sickle Cell Disease Program Annual Meeting Conference Proceedings. 2000:175a.
5. Koshy M, Askin M, McMahon L, Adams-Graves P, Halloway L, Faller DV, et al. Arginine butyrate in sickle cell leg ulcers: interim findings of a randomized phase II trial [abstract]. The National Sickle Cell Disease Program Annual Meeting Conference Proceedings. 2001:Abstract no: 124.
6. Koshy M, Edinburgh L, McMahon L, Adams-Graves P, Halloway L, Faller DV, et al. Arginine butyrate in sickle cell leg ulcers: interim findings of a phase II trial [abstract]. Blood 1999;Suppl:417a.
7. McMahon L, Tamary H, Askin M, Adams-Graves P, Eberhardt RT, Sutton M, et al. A randomized phase II trial of Arginine Butyrate with standard local therapy in refractory sickle cell leg ulcers. British Journal of Haematology 2010;151(5):516-24. [PUBMED: 20955402]
8. McMahon LC, Askin M, Koshy M, Tamary H, Atweh GF, Adam-Graves P, et al. A phase II trial of arginine butyrate in refractory sickle cell leg ulcers [abstract]. Blood 2002;100 (11 Pt 1 of 2):10a-1a.
9. Serjeant GR, Howard C. Isoxsuprine hydrochloride in the therapy of sickle cell leg ulceration. West Indian Medical Journal 1977;26(3):164-6. [PUBMED: 333769]
10. Serjeant BE, Harris J, Thomas P, Serjeant GR. Propionyl-L-carnitine in chronic leg ulcers of homozygous sickle cell disease: a pilot study. Journal of the American Academy of Dermatology 1997;37(3 Pt 1):491-3. [PUBMED: 9308570]
11. Ramirez GM, Wethers DL, Koshy M, Steinberg MH, Phillips G Jr, Siegel RS, et al. Accelerated healing of chronic sickle cell leg ulcers treated with a RGD matrix. The National Sickle Cell Disease Program Annual Meeting Conference Proceedings. 1994.
12. Wethers DL, Ramirez GM, Koshy M, Steinberg MH, Phillips G Jr, Siegel RS, et al. Accelerated healing of chronic sickle-cell leg ulcers treated with RGD peptide matrix. RGD Study Group. Blood 1994;84(6):1775-9. [PUBMED: 8080985]
13. AfifiAM, Adnan M, Taha M, Amasha ME. Xanthinol nicotinate in the management of leg ulcers associated with haemoglobinopathies. Current Medical Research and Opinion 1979, issue 5:309-13. [PUBMED: 80156092]
14. Cacciola E, Giustolisi R, Musso R, Longo A, Cacciola E. Antithrombin III concentrate for treatment of chronic leg ulcers in sickle cell-beta thalassemia: a pilot study. Annals of Internal Medicine 1990;111(6):534-6. [PUBMED: 2774375]
15. Lucena A, Souza K, Anselmo C, Nascimento A, Araújo A. InGaP (670nm) laser use in the leg ulcer healing in patients with sickle cell anemia [O uso do laser de ingap (670nm) na cicatrização de úlceras de perna em pacientes com anemia falciforme]. Anais da Faculdade de Medicina da Universidade Federal de Pernambuco 2007;52(1):45-50. [: LILACS ID: 495328]
16. Neves AF, Martins A, Queiroz AMM, Thomé ED, Queiroz APA, Lobo CLC. Evaluation of the topical application of opioid analgesia for a leg ulcer of a sickle cell disease patient [Avaliação da analgesia de opioide tópico em úlcera de perna de paciente falcêmico]. Revista Brasileira de Hematologia e Hemoterapia 2010;32(2):123-5. [: LILACS ID: lil-553486]
17. Okany CC, Atimomo CE, Akinyanju OO. Efficacy of natural honey in the healing of leg ulcers in sickle cell anaemia. The Nigerian Postgraduate Medical Journal 2004;11(3):179-81. [PUBMED: 15505645]
18. Paggiaro AO, de Carvalho VF, Fonseca GHH, Doi A, Ferreira MC. Negative pressure therapy for complex wounds in patients with sickle-cell disease: a case study. Ostomy Wound Management 2010;56(8):62-7. [: IDS Number: 644CO]
19. Sawyer PN, Haque S, Reddy K, Sophie Z, Feller J. Wound healing effects of debrisan on varicose, postoperative, decubitus, and sickle-cell ulcers in man. Vascular Surgery 1979; Vol. 13, issue 4:251-6.
20. Serjeant GR, Galloway RE, Gueri MC. Oral zinc sulphate in sickle-cell ulcers. Lancet 1970; Vol. 2, issue 7679:891-2. [PUBMED: 4097279]
21. Akinsheye I, Klings ES. Sickle cell anemia and vascular dysfunction: the nitric oxide connection. Journal of Cellular Physiology 2010;224(3):620-5. [PUBMED: 20578237]
22. Akinyanju O, Akinsete I. Leg ulceration in sickle cell disease in Nigeria. Tropical and Geographical Medicine 1979;31:87-91. [PUBMED: 483376]
23. al-Momen AK. Recombinant human erythropoietin induced rapid healing of a chronic leg ulcer in a patient with sickle cell disease. Acta Haematologica 1991;86:46-8. [PUBMED: 1950363]
24. Alexander N, Higgs D, Dover G, Serjeant GR. Are there clinical phenotypes of homozygous sickle cell disease?. British Journal of Haematology 2004;126:606-11. [PUBMED: 15287956]
25. Alikhan MA, Carter G, Mehta P. Topical GM-CSF hastens healing of leg ulcers in sickle cell disease. American Journal of Hematology 2004;76:192. [PUBMED: 15164391]
26. Alleyne SI, Wint E, Serjeant GR. Social effects of leg ulceration in sickle cell anemia. Southern Medical Journal 1977;70:213-4. [PUBMED: 841405]
27. Amini-Adle M, Auxenfants C, Allombert-Blaise C, Deroo-Berger MC, Ly A, Jullien D, et al. Rapid healing of long-lasting sickle cell leg ulcer treated with allogeneic keratinocytes. Journal of the European Academy of Dermatology and Venereology 2007;21:707-8. [PUBMED: 17448004]
28. Ankra-Badu GA. Sickle cell leg ulcers in Ghana. East African Medical Journal 1992;69:366-9. [PUBMED: 1396190]
29. Anonymous. Methodological standards and patient-centeredness in comparative effectiveness research: the PCORI perspective. JAMA 2012;307(15):1636-40. [PUBMED: 22511692]
30. Aslan M, Freeman BA. Redox-dependent impairment of vascular function in sickle cell disease. Free Radical Biology & Medicine 2007;43:1469-83. [PUBMED: 17964418]
31. Asnani MR, Lipps GE, Reid ME. Utility of WHOQOL-BREF in measuring quality of life in sickle cell disease. Health and Quality of Life Outcomes 2009;7:75. [PUBMED: 19664266]
32. Ballas SK. Treatment of painful sickle cell leg ulcers with topical opioids. Blood 2002;99:1096. [PUBMED: 11822360]
33. Ballas SK, LieffS, Benjamin LJ, Dampier CD, Heeney MM, Hoppe C, et al. Definitions of the phenotypic manifestations of sickle cell disease. American Journal of Hematology 2010;85(1):6-13. [PUBMED: 19902523]
34. Balshem H, Helfand M, Schunemann HJ, Oxman AD, Kunz R, Brozek J, et al. GRADE guidelines: 3. Rating the quality of evidence. Journal of Clinical Epidemiology 2011;64(4):401-6. [PUBMED: 21208779]
35. Bardakdjian-Michau J, Bahuau M, Hurtrel D, Godart C, Riou J, Mathis M, et al. Neonatal screening for sickle cell disease in France. Journal of Clinical Pathology 2009;62:31-3. [PUBMED: 19103855]
36. Bender DA. A dictionary of food and nutrition. 3rd Edition. New York: Oxford University Press, 2009. [: 978-0-19-923487-5]
37. Bergin SM, Wraight P. Silver based wound dressings and topical agents for treating diabetic foot ulcers. Cochrane Database of Systematic Reviews 2006, Issue 1. [DOI: 10.1002/14651858.CD005082.pub2]
38. Cacciola E, Giustolisi R, Musso R, Longo A, Cacciola E. Antithrombin III concentrate for treatment of chronic leg ulcers in sickle cell-beta thalassemia: a pilot study. Annals of Internal Medicine 1989;111:534-6. [PUBMED: 2774375]
39. Cacciola E, Musso R, Giustolisi R, Cacciola E, Alessi M. Blood hypercoagulability as a risk factor for leg ulcers in sickle cell disease. Blood 1990;75(12):2467-8. [PUBMED: 2350585]
40. Chalchal H, Rodino W, Hussain S, Haq I, Panetta T, Solomon W, Gillette P, et al. Impaired venous hemodynamics in a minority of patients with chronic leg ulcers due to sickle cell anemia. VASA. Zeitschrift für Gefässkrankheiten. Journal for Vascular Diseases 2001;30:277-9. [PUBMED: 11771212]
41. Clare A, FitzHenley M, Harris J, Hambleton I, Serjeant GR. Chronic leg ulceration in homozygous sickle cell disease: the role of venous incompetence. British Journal of Haematology 2002;119:567-71. [PUBMED: 12406102]
42. Clarke M. Standardising outcomes for clinical trials and systematic reviews. Trials 2007;8:39. [PUBMED: 18039365]
43. Creary M, Williamson D, Kulkarni R. Sickle cell disease: current activities, public health implications, and future directions. Journal of Women's Health 2007;16:575-82. [PUBMED: 17627395]
44. Cumming V, King L, Fraser R, Serjeant G, Reid M. Venous incompetence, poverty and lactate dehydrogenase in Jamaica are important predictors of leg ulceration in sickle cell anaemia. British Journal of Haematology 2008;142:119-25. [PUBMED: 18477043]
45. Daudt LE, Zechmaister D, Portal L, Neto EC, Silla LM, Giugliani R. Neonatal screening for hemoglobinopathies: a pilot study in Porto Alegre, Rio Grande do Sul, Brazil [Triagem neonatal para hemoglobinopatias: um estudo piloto em Porto Alegre, Rio Grande do Sul, Brasil]. Cadernos de Saúde Pública 2002;18:833-41. [PUBMED: 12048609]
46. Durosinmi MA, Gevao SM, Esan GJ. Chronic leg ulcers in sickle cell disease: experience in Ibadan, Nigeria. African Journal of Medicine and Medical Sciencies 1991;20:11-4. [PUBMED: 1905464]
47. Eckman JR. Leg ulcers in sickle cell disease. Hematology/Oncology Clinics of North America 1996;10:1333-44. [PUBMED: 8956020]
48. Edwards J. Debridement of diabetic foot ulcers. Cochrane Database of Systematic Reviews 2002, Issue 4. [DOI: 10.1002/14651858.CD003556.pub2]
49. Espinosa Martínez E, Villarreal Piloto C, Torres A, González A. Hyperbaric oxygen in the treatment of malleolar ulcer from sickle cell anemia [Oxigeno hiperbárico en el tratamiento de la úlcera maleolar de la anemia drepanocitica]. Revista Cubana de Hematología, Inmunología y Hemoterapia 1992;8:28-36. [: 112188]
50. Frost ML, Treadwell P. Treatment of sickle cell leg ulcers with pentoxifylline. International Journal of Dermatology 1990;29:375-6. [PUBMED: 2361798]
51. Gabriel SE, Normand SL. Getting the Methods Right - The Foundation of Patient-Centered Outcomes Research. The New England Journal of Medicine 2012; Vol. Jul 25:Epub ahead of print. [PUBMED: 22830434]
52. Gordon S, Bui A. Human skin equivalent in the treatment of chronic leg ulcers in sickle cell disease patients. Journal of the American Podiatry Association 2003;93:240-1. [PUBMED: 12756317]
53. www.gradepro.org. GRADEpro. 20th October 2014. McMaster University, 2014.
54. Gulbis B, Ferster A, Cotton F, Lebouchard MP, Cochaux P, Vertongen F. Neonatal haemoglobinopathy screening: review of a 10-year programme in Brussels. Journal of Medical Screening 2006;13:76-8. [PUBMED: 16792829]
55. Guyatt GH, Oxman AD, Kunz R, Brozek J, Alonso-Coello P, Rind D, et al. GRADE guidelines 6. Rating the quality of evidence--imprecision. Journal of Clinical Epidemiology 2011;64(12):1283-93. [PUBMED: 21839614]
56. Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, et al. GRADE guidelines: 7. Rating the quality of evidence--inconsistency. Journal of Clinical Epidemiology 2011;64(12):1294-302. [PUBMED: 21803546]
57. Guyatt GH, Oxman AD, Montori V, Vist G, Kunz R, Brozek J, et al. GRADE guidelines: 5. Rating the quality of evidence--publication bias. Journal of Clinical Epidemiology 2011;64(12):1277-82. [PUBMED: 21802904]
58. Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, et al. GRADE guidelines: 8. Rating the quality of evidence--indirectness. Journal of Clinical Epidemiology 2011;64(12):1303-10. [PUBMED: 21802903]
59. Guyatt GH, Oxman AD, Sultan S, Glasziou P, Akl EA, Alonso-Coello P, et al. GRADE guidelines: 9. Rating up the quality of evidence. Journal of Clinical Epidemiology 2011;64(12):1311-6. [PUBMED: 21802902]
60. Guyatt GH, Oxman AD, Vist G, Kunz R, Brozek J, Alonso-Coello P, et al. GRADE guidelines: 4. Rating the quality of evidence--study limitations (risk of bias). Journal of Clinical Epidemiology 2011;64(4):407-15. [PUBMED: 21247734]
61. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology 2011;64(4):383-94. [PUBMED: 21195583]
62. Guyatt GH, Oxman AD, Kunz R, Atkins D, Brozek J, Vist G, et al. GRADE guidelines: 2. Framing the question and deciding on important outcomes. Journal of Clinical Epidemiology 2011;64(4):395-400. [PUBMED: 21194891]
63. Guyatt GH, Oxman AD, Schunemann HJ, Tugwell P, Knottnerus A. GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. Journal of Clinical Epidemiology 2011;64(4):380-2. [PUBMED: 21185693]
64. Guyatt G, Oxman AD, Sultan S, Brozek J, Glasziou P, Alonso-Coello P, et al. GRADE guidelines 11-making an overall rating of confidence in effect estimates for a single outcome and for all outcomes. Journal of Clinical Epidemiology 2012;Apr 27:Epub print. [PUBMED: 22542023]
65. Hagar W, Vichinsky E. Advances in clinical research in sickle cell disease. British Journal of Haematology 2008;141:346-56. [PUBMED: 18341629]
66. Halabi-Tawil M, Lionnet F, Girot R, Bachmeyer C, Levy PP, Aractingi S. Sickle cell leg ulcers: a frequently disabling complication and a marker of severity. British Journal of Dermatology 2008;158:339-44. [PUBMED: 18047512]
67. Harrell HL Jr. L-carnitine for leg ulcers. Annals of Internal Medicine 1990;113:412. [PUBMED: 2382928]
68. Henthorn JS, Almeida AM, Davies SC. Neonatal screening for sickle cell disorders. British Journal of Haematology 2004;124:259-63. [PUBMED: 14717772]
69. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60. [PUBMED: 12958120]
70. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane Collaboration. Available from www.cochrane-handbook.org 2011; Vol. Version 5.1.0 [updated March 2011].
71. Higgins JPT, Altman DG (editors). Chapter 8: Assessing risk of bias in included studies. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
72. Higgins JPT, Deeks JJ, Altman DG on behalf of the CSMG. Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors). Cochrane Handbook of Systematic Reviews of Interventions. Version 5.1 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
73. Hopewell S, Clarke M, Higgins JPT (editors). Core reporting of outcomes in effectiveness trials. Cochrane Methods. Cochrane DB Syst Rev 2010; Vol. Suppl 1:1-29. [: ISSN 2044-4702]
74. Ioannidis JP, Evans SJ, Gotzsche PC, O'Neill RT, Altman DG, Schulz K, et al. Better reporting of harms in randomized trials: an extension of the CONSORT statement. Annals of Internal Medicine 2004;141(10):781-8. [PUBMED: 15545678]
75. Ioannidis JP. Meta-research: The art of getting it wrong. Research Synthesis Methods 2010;1(3-4):169-84.
76. Kato GJ, Gladwin MT, Steinberg MH. Deconstructing sickle cell disease: reappraisal of the role of hemolysis in the development of clinical subphenotypes. Blood Reviews 2007;21:37-47. [PUBMED: 17084951]
77. Kato GJ, Hebbel RP, Steinberg MH, Gladwin MT. Vasculopathy in sickle cell disease: Biology, pathophysiology, genetics, translational medicine, and new research directions. American Journal of Hematology 2009;84:618-25. [PUBMED: 19610078]
78. Kirkham JJ, Dwan KM, Altman DG, Gamble C, Dodd S, Smyth R, et al. The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews. BMJ 2010;340:c365. [PUBMED: 20156912]
79. Knox-Macaulay HH. Sickle cell disease in Sierra Leone: a clinical and haematological analysis in older children and adults. Annals of Tropical Medicine and Parasitology 1983;77:411-9. [PUBMED: 6639186]
80. Koshy M, Entsuah R, Koranda A, Kraus AP, Johnson R, Bellvue R, et al. Leg ulcers in patients with sickle cell disease. Blood 1989;74:1403-8. [PUBMED: 2475188]
81. La Grenade L, Thomas PW, Serjeant GR. A randomized controlled trial of solcoseryl and duoderm in chronic sickle-cell ulcers. West Indian Medical Journal 1993;42:121-3. [PUBMED: 8273321]
82. Lionnet F, Bachmeyer C, Stankovic K, Tharaux PL, Girot R, Aractingi S. Efficacy of the endothelin receptor blocker bosentan for refractory sickle cell leg ulcers. British Journal of Haematology 2008;142:991-2. [PUBMED: 18671710]
83. MacFarlane DE, Baum KF, Serjeant GR. Bacteriology of sickle cell leg ulcers. Transactions of the Royal Society of Tropical Medicine and Hygiene 1986;80:553-6. [PUBMED: 3101240]
84. Mack AK, Kato GJ. Sickle cell disease and nitric oxide: a paradigm shift?. The International Journal of Biochemistry & Cell Biology 2006;38:1237-43. [PUBMED: 16517208]
85. Makani J, Williams TN, Marsh K. Sickle cell disease in Africa: burden and research priorities. Annals of Tropical Medicine and Parasitology 2007;101:3-14. [MEDLINE: 17244405]
86. Martin E. Concise Medical Dictionary. 8th Edition. New York: Oxford University Press, 2011.
87. Mañú Pereira M, Corrons JL. Neonatal haemoglobinopathy screening in Spain. Journal of Clinical Pathology 2009;62:22-5. [PUBMED: 19103853]
88. Mery L, Girot R, Aractingi S. Topical effectiveness of molgramostim (GM-CSF) in sickle cell leg ulcers. Dermatology 2004;208:135-7. [PUBMED: 15057003]
89. Minniti CP, Eckman J, Sebastiani P, Steinberg MH, Ballas SK. Leg ulcers in sickle cell disease. American Journal of Hematology 2010;85(10):831-3. [MEDLINE: 20872960]
90. Modell B, Darlison M. Global epidemiology of haemoglobin disorders and derived service indicators. Bulletin of the World Health Organization 2008;86:480-7. [PUBMED: 18568278]
91. Mohan JS, Marshall JM, Reid HL, Thomas PW, Serjeant GR. Postural vasoconstriction and leg ulceration in homozygous sickle cell disease. Clinical Science 1997;92:153-8. [PUBMED: 9059316]
92. Mohan JS, Vigilance JE, Marshall JM, Hambleton IR, Reid HL, Serjeant GR. Abnormal venous function in patients with homozygous sickle cell (SS) disease and chronic leg ulcers. Clinical Science 2000;98:667-72. [PUBMED: 10814603]
93. Moher D, Hopewell S, Schulz KF, Montori V, Gøtzsche PC, Devereaux PJ, et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ 2010;340:c869. [MEDLINE: 20332511]
94. Moore ZEH, Cowman S. Wound cleansing for pressure ulcers. Cochrane Database of Systematic Reviews 2005, Issue 4. [DOI: 10.1002/14651858.CD004983.pub2]
95. Morgan AG, Venner AM. Immunity and leg ulcers in homozygous sickle cell disease. Journal of Clinical & Laboratory Immunology 1981;6:51-5. [PUBMED: 7265175]
96. Morris CR. Mechanisms of vasculopathy in sickle cell disease and thalassemia. Hematology/the Education Program of the American Society of Hematology. American Society of Hematology. Education Program 2008; Vol. 2008, issue 1:177-85. [PUBMED: 19074078]
97. Mousa SA, Qari MH. Diagnosis and management of sickle cell disorders. Methods in Molecular Biology 2010;663:291-307. [PUBMED: 20617425]
98. Nebeker JR, Barach P, Samore MH. Clarifying adverse drug events: a clinician's guide to terminology, documentation, and reporting. Annals of Internal Medicine 2004;140(10):795-801. [PUBMED: 15148066]
99. Nelson EA, Bell-Syer SEM, Cullum NA. Compression for preventing recurrence of venous ulcers. Cochrane Database of Systematic Reviews 2000, Issue 4. [DOI: 10.1002/14651858.CD002303]
100. Nolan VG, Baldwin C, Wang L, Ma Q, Wyszynski DF, Farrell JJ, Sebastiani P, et al. Sickle Cell Leg Ulcers: Associations with Haemolysis and SNPs in Klotho, TEK and Genes of the TGF-beta/BMP Pathway. British Journal of Haematology 2006;133(5):570-8. [PUBMED: 16681647]
101. O'Meara S, Cullum N, Majid M, Sheldon T. Systematic reviews of wound care management: (3) antimicrobial agents for chronic wounds; (4) diabetic foot ulceration. Health Technology Assessment 2000;4(21):1-237. [PUBMED: 11074391]
102. O'Meara S, Cullum NA, Nelson EA. Compression for venous leg ulcers. Cochrane Database of Systematic Reviews 2009, Issue 1. [DOI: 10.1002/14651858.CD000265.pub2]
103. O'Meara S, Al-Kurdi D, Ovington LG. Antibiotics and antiseptics for venous leg ulcers. Cochrane Database of Systematic Reviews 2010, Issue 1. [DOI: 10.1002/14651858.CD003557.pub3]
104. Ofosu MD, Castro O, Alarif L. Sickle cell leg ulcers are associated with HLA-B35 and Cw4. Archives of Dermatology 1987;123(4):482-4. [PUBMED: 3493733]
105. Orkin SH, Higgs DR. Medicine. Sickle cell disease at 100 years. Science (New York, N.Y.) 2010;329(5989):291-2. [PUBMED: 20647458]
106. Paladino SF. Leg ulcers in sickle cell disease. Revista Brasileira de Hematologia e Hemoterapia 2007;29:288-90. [: 470902]
107. Palfreyman SSJ, Nelson EA, Lochiel R, Michaels JA. Dressings for healing venous leg ulcers. Cochrane Database of Systematic Reviews 2006, Issue 3. [DOI: 10.1002/14651858.CD001103.pub2]
108. Pieters RC, Rojer RA, Saleh AW, Saleh AE, Duits AJ. Molgramostim to treat SS-sickle cell leg ulcers. Lancet 1995;345:528. [PUBMED: 7861910]
109. Porta M (ed). Dictionary of Epidemiology. 5th Edition. New York: Oford University Press, 2008. [: ISBN 978-0-19-531449-6]
110. Prabhakar H, Haywood C Jr, Molokie R. Sickle cell disease in the United States: looking back and forward at 100 years of progress in management and survival. American Journal of Hematology 2010;85(5):346-53. [PUBMED: 20425797]
111. Ramalho AS, Velloso LA, Diniz M. Sickle cell syndromes and ulcer of inferior extremities [Síndromes falcêmicas e úlceras de membros inferiores]. Anais Brasileiros de Dermatologia 1985;60:307-10. [: 29971]
112. Rees DC, Williams TN, Gladwin MT. Sickle-cell disease. Lancet 2010;376(9757):2018-31. [PUBMED: 21131035]
113. Reindorf CA, Walker-Jones D, Adekile AD, Lawal O, Oluwole SF. Rapid healing of sickle cell leg ulcers treated with collagen dressing. Journal of the National Medical Association 1989;81:866-8. [PUBMED: 2769790]
114. Rice SM. Healing of chronic sicklemia leg ulcers healed by cortisone. A.M.A. Archives of Dermatology and Syphilology 1953;68:576-9. [PUBMED: 13091419]
115. Santen SA. Transfusion therapy. In: Tintinalli JE, Kellen GD, Stapczynski JS editor(s). Emergency Medicine: A comprehensive study guide. 6th Edition. New York: McGraw Hill, 2004:1348-53. [: 0-07138875-3]
116. Schleucher R, Gaessler M, Knobloch J. Rapid healing of a late diagnosed sickle cell leg ulcer using a new combination of treatment methods. Journal of Wound Care 2007;16(5):197-8. [PUBMED: 17552401]
117. Sehgal SC, Arunkumar BK. Microbial flora and its significance in pathology of sickle cell disease leg ulcers. Infection 1992;20(2):86-8. [PUBMED: 1582689]
118. Serarslan G, Akgül F, Babayigit C. High prevalence of pulmonary hypertension in homozygous sickle cell patients with leg ulceration. Clinical and Experimental Hypertension 2009;31(1):44-8. [PUBMED: 19172458]
119. Serjeant GR, Serjeant BE, Mohan JS, Clare A. Leg ulceration in sickle cell disease: medieval medicine in a modern world. Hematology/Oncology Clinics of North America 2005;19(5):943-56. [PUBMED: 16214654]
120. Serjeant GR. One hundred years of sickle cell disease. British Journal of Haematology 2010;151(5):425-9. [PUBMED: 20955412]
121. Sher GD, Olivieri NF. Rapid healing of chronic leg ulcers during arginine butyrate therapy in patients with sickle cell disease and thalassemia. Blood 1994;84(7):2378-80. [PUBMED: 7919358]
122. Smith F, Dryburgh N, Donaldson J, Mitchell M. Debridement for surgical wounds. Cochrane Database of Systematic Reviews 2011, Issue 5. [DOI: 10.1002/14651858.CD006214.pub3]
123. Spence RJ. The use of a free flap in homozygous sickle cell disease. Plastic and Reconstructive Surgery 1985;76(4):616-9. [MEDLINE: 4034781]
124. Steinberg MH. Genetic etiologies for phenotypic diversity in sickle cell anemia. Scientific World Journal 2009;9:46-67. [PUBMED: 19151898]
125. Taylor JG 6th, Nolan VG, Mendelsohn L, Kato GJ, Gladwing MT, Steinberg MH. Chronic hyper-hemolysis in sickle cell anemia: association of vascular complications and mortality with less frequent vasooclussive pain. PloSOne 2008;3:e2095. [PUBMED: 18461136]
126. Trent JT, Kirsner RS. Leg ulcers in sickle cell disease. Advances in Skin & Wound Care 2004;17(8):410-6. [PUBMED: 15492676]
127. Tshilolo L, Kafando E, Sawadogo M, Cotton F, Vertongen F, Ferster A, et al. Neonatal screening and clinical care programmes for sickle cell disorders in sub-Saharan Africa: lessons from pilot studies. Public Health 2008;122(9):933-41. [PUBMED: 18555498]
128. Vermeulen H, Ubbink DT, Goossens A, de Vos R, Legemate DA. Dressings and topical agents for surgical wounds healing by secondary intention. Cochrane Database of Systematic Reviews 2004, Issue 1. [DOI: 10.1002/14651858.CD003554.pub2]
129. Wasiak J, Cleland H, Campbell F. Dressings for superficial and partial thickness burns. Cochrane Database of Systematic Reviews 2008, Issue 4. [DOI: 10.1002/14651858.CD002106.pub3]
130. Weatherall D, Akinyanju O, Fucharoen S, Olivieri N, Musgrove P. Inherited Disorders of Hemoglobin. Disease Control Priorities in Developing Countries. 2nd Edition. Washington DC: The World Bank and Oxford University Press, 2006.
131. Wilkinson EAJ, Hawke CC. Oral zinc for arterial and venous leg ulcers. Cochrane Database of Systematic Reviews 1998, Issue 4. [DOI: 10.1002/14651858.CD001273]
132. Wood KC, Hsu LL, Gladwin MT. Sickle cell disease vasculopathy: a state of nitric oxide resistance. Free Radical Biology and Medicine 2008;44(8):1506-28. [PUBMED: 18261470]
133. Martí-Carvajal AJ, Knight-Madden JM, Martinez-Zapata MJ. Interventions for treating leg ulcers in people with sickle cell disease. Cochrane Database of Systematic Reviews 2012, Issue 11. [DOI: 10.1002/14651858.CD008394.pub2]